PTPN1 and atherosclerosis: Based on these findings we hypothesized that myeloid-PTP1B inhibition may ameliorate systemic atherosclerosis by improving the balance of cholesterol influx- and clearance from early lesions and by enhancing the clearance of lipoproteins towards biliary excretion through KCs.